Inhibitory effect of angiotensin TT receptor antagonist on hepatic stellate cell activation in non-a

• 作 者: Shiro Yokohama Yoshihiko Tokusashi Kimihide Nakamura Yosui Tamaki Satoshi Okamoto Mituyoshi Okada Kazunobu Aso Takenao Hasegawa Masaru Aoshima Naoyuki Miyokawa Masakazu Haneda Masashi Yoneda
• 机 构: Second Department of Medicine,Asahikawa Medical College, Asahikawa, Japan“,”Health Care Administrati
• 出 处: 世界胃肠病学杂志（英文版）
• 发表日期: 2006年2期
• 关键词: NASH NAFLD Hepatic fibrosis HSC Losartan

AIM: To investigate the efficacy of angiotensin Ⅱ receptor antagonist on hepatic stellate cells (HSCs) activation in the patients with non-alcoholic steatohepatitis (NASH).METHODS: Seven patients with NASH were prescribed losartan, a selective angiotensin Ⅱ type 1 receptor antagonist (50 mg/d) for 48 wk. Liver biopsies were performed both at the entry and end of the study in all patients. Quiescent and activated HSCs were identified by double immunostaining using anti-p75 and α-smooth muscle actin antibodies, and the number of each phenotype was counted. Similarly, the liver specimens obtained from the eight patients with non-alcoholic fatty liver (NAFL) were also examined as controls.RESULTS: In NASH hepatic tissues, activated HSCs were dominantly distributed as compared with those in NAFL.The 48-wk losartan treatment induced a remarkable decrease in activated HSCs and a mild increase in quiescent phenotypes.CONCLUSION: Our data suggest the crucial involvement of HSCs in anti-fibrotic effect of angiotensin Ⅱ receptor antagonist on patients with NASH.